eGFR (Cystatin C)

Your standard kidney number on a basic metabolic panel can quietly mislead you. If you carry a lot of muscle, very little muscle, are older, or take certain medications, the creatinine-based estimate of kidney function can look reassuringly normal while your kidneys are actually losing ground.

Cystatin C-based eGFR (estimated glomerular filtration rate) is the workaround. It uses a different protein in your blood, one that is far less swayed by muscle mass and diet, to give you a cleaner read on how well your kidneys are filtering. In many people, it surfaces hidden risk that creatinine alone misses.

What This Number Actually Reflects

This test does not measure a hormone or an enzyme. It plugs your blood cystatin C level into an equation along with your age to estimate how many milliliters of blood your kidneys clean per minute. Cystatin C itself is a small protein made by essentially every cell in your body that has a nucleus, and it is released at a relatively constant rate.

Because cystatin C is freely filtered by the kidneys and then broken down by tubular cells rather than returned to the bloodstream, the amount left in your blood reflects how well your filtering units (the glomeruli, the tiny filters inside the kidney) are working. Higher cystatin C in blood usually means lower filtration, which translates to a lower eGFR number on your report.

Why It Often Beats the Standard Kidney Estimate

Creatinine is a waste product of muscle, so the standard creatinine-based estimate is pulled around by how much muscle you have, how much meat you eat, your sex, and your age. Cystatin C is far less influenced by those factors. In a large validation study, the combined creatinine-plus-cystatin C equation produced an estimate within 30% of true measured filtration in 91.5% of people, compared with 85.9% for cystatin C alone and 87.2% for creatinine alone. The combined equation outperformed either single-marker equation.

It also reclassifies people more accurately. When creatinine-based eGFR landed in the borderline 45 to 59 zone, the combined equation correctly moved a meaningful fraction of those people up to a filtration rate of 60 or higher, meaning they did not actually have chronic kidney disease. In other words, cystatin C cuts both ways: it can confirm a real problem or clear someone who only looked sick on paper.

This is why guideline bodies have shifted. The 2024 KDIGO (Kidney Disease Improving Global Outcomes) guideline and the 2021 race-free CKD-EPI update both recommend wider use of cystatin C as a complementary marker, because it does not differ by race the way creatinine does and correlates better with hard outcomes.

Heart Attack and Stroke Risk

Low kidney filtration is one of the most consistent non-traditional risk factors for cardiovascular disease, and cystatin C-based estimates surface that risk earlier and more sharply than creatinine. In the BiomarCaRE project, which combined tens of thousands of adults from 20 European population cohorts, having chronic kidney disease defined by cystatin C carried a roughly twofold higher risk of dying from cardiovascular disease compared with people without CKD, and that signal was stronger than the same comparison using creatinine.

UK Biobank reinforces this. In an analysis of more than 440,000 adults, cystatin C-based eGFR was the kidney measure most strongly associated with cardiovascular events and death, beating traditional creatinine measures after adjusting for standard atherosclerotic risk factors. In a separate UK Biobank analysis of about 297,000 participants followed for over a decade, people whose cystatin C-based estimate was substantially lower than their creatinine-based estimate had about 49% higher risk of cardiovascular events and 44% higher all-cause mortality.

In people who already have stable coronary disease, the signal is even more direct. Across about 7,800 participants in the LIPID trial followed for six years, those in the top quarter of cystatin C had about 47% higher risk of major cardiovascular events than those in the bottom quarter, even after full adjustment for traditional risk factors.

Chronic Kidney Disease and Progression

Cystatin C-based eGFR is built for this question. In a real-world study of 435 people with chronic kidney disease, the combined creatinine-cystatin C equation correctly classified 94.9% of patients within 30% of true measured filtration, the best of any equation tested. In people with early diabetic kidney disease, cystatin C-based estimates flagged kidney impairment that creatinine missed.

It is also better for catching kidney disease in older adults. In a Stockholm cohort of 82,154 people aged 65 or older, an eGFR of 60 versus 80 mL/min/1.73 m squared carried a 30% to 40% higher mortality risk by cystatin C, while the same comparison by creatinine showed little to no risk. The creatinine-based estimate was effectively flat where cystatin C was clearly tracking real disease.

Mortality Across the Board

A 2025 systematic review of 18 studies looking at people whose cystatin C-based estimate was substantially lower than their creatinine-based estimate found a 58% higher risk of death and a 32% higher risk of cardiovascular events. The reverse pattern, where cystatin C was higher than creatinine would suggest, carried lower mortality risk.

Put plainly: when these two estimates disagree, the cystatin C reading is usually closer to the truth, and it predicts who lives and who does not better than creatinine alone.

Hospital Settings and Acute Kidney Injury

After acute kidney injury, cystatin C-based eGFR labels more people as still having ongoing chronic kidney disease at three months (69.6%) than creatinine does (44.9%), and that extra detection matters for long-term risk. After cardiac surgery, cystatin C measured 10 hours post-operation strongly flagged patients heading toward kidney injury, with the highest quartile carrying about 13 times the odds compared with the lowest quartile.

The flip side: during active acute illness or rapidly changing kidney function, all eGFR equations (cystatin C included) become less reliable because they assume your biomarker level is at steady state. A single value during a hospital stay should not be treated as your true baseline.

When Results Can Be Misleading

Cystatin C is cleaner than creatinine, but it is not bulletproof. A few situations can shift the number without your kidneys actually changing:

• Corticosteroids: prednisone and similar steroids raise cystatin C and make your eGFR look falsely lower. A study in heart failure patients showed cystatin C jumped from 1.24 to 1.61 mg/L over about two weeks of prednisone without any actual loss of kidney function. The effect is dose-dependent and clinically meaningful at prednisolone-equivalent doses of about 0.17 mg/kg/day or higher.
• Thyroid disease and inflammation: uncontrolled thyroid dysfunction, active inflammation (high CRP), obesity, smoking, and certain cancers can shift cystatin C without changing kidney filtration. Interpret with caution if any of these apply.
• Acute illness or recent surgery: in the first 24 to 72 hours after surgery or during a serious infection, cystatin C may not yet reflect your true kidney function. Levels measured in this window can either over- or under-shoot reality.
• Certain cancer drugs: CDK4/6 inhibitors, some tyrosine kinase inhibitors, and similar targeted agents distort creatinine without harming the kidneys. Cystatin C-based eGFR generally remains accurate in this setting, which is one of its biggest practical strengths.

Tracking Your Trend Over Time

A single reading is a snapshot. Cystatin C has biological variability, can be nudged by transient conditions, and is most informative when you see it move (or stay stable) over months and years. Research in CKD specifically found that one baseline cystatin C value missed risk patterns that became clear once measurements were repeated annually.

A reasonable cadence for a proactive adult: get a baseline now, retest in 3 to 6 months if you are actively changing diet, weight, blood pressure, blood sugar, or kidney-relevant medications, and then at least annually thereafter. If your baseline is borderline or your creatinine and cystatin C estimates disagree, lean toward the more frequent end.

What you are watching for is the slope, not the single number. A stable cystatin C-based eGFR year after year is reassuring even if it sits at the lower end of normal. A steady downward drift, even within the normal range, deserves attention long before a single value crosses a threshold.

What to Do With an Unexpected Result

If your cystatin C-based eGFR comes back lower than expected, especially if it disagrees with your creatinine-based estimate by more than 30%, the next steps are about confirmation and context, not panic. Pair it with a urine albumin-to-creatinine ratio (UACR) to look for actual kidney damage, repeat the test in 4 to 12 weeks after any acute illness or steroid course has resolved, and check whether obvious confounders (active inflammation, thyroid problems, recent surgery) could explain the result.

If the discordance between cystatin C and creatinine estimates is larger than 40% and cannot be explained by these factors, a measured GFR using an external tracer is the reference-standard next step. For high-stakes decisions like drug dosing in cancer chemotherapy, kidney donor evaluation, or deciding whether to start a kidney-protective medication, this confirmatory testing is worth pursuing. A nephrologist consult makes sense when the pattern is persistent or progressive.

The pattern that warrants the most concern is a cystatin C-based eGFR that is consistently lower than your creatinine-based estimate, accompanied by any albumin in the urine, in someone with diabetes, high blood pressure, or a family history of kidney disease. That combination outperforms either test alone for predicting who will progress, who will have a cardiovascular event, and who will die earlier.